Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor

被引:108
|
作者
Komatsu, M
Jepson, S
Arango, ME
Carraway, CAC
Carraway, KL [1 ]
机构
[1] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA
[2] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA
关键词
Muc4; apoptosis; ErbB2; xenotransplanted tumor; tumor growth; sialomucin complex;
D O I
10.1038/sj.onc.1204106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of the membrane mucin MUC4/Sialo-mucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies, As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells, SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the effect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC upregulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not significantly increase proliferation of A375 cells in vitro, Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors, These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis, Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic effect of SMC is independent of tumor-host interactions, These findings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the first time evidence for the regulation of programmed cell death by a gene of the MUC family.
引用
收藏
页码:461 / 470
页数:10
相关论文
共 50 条
  • [41] Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
    Gupta, Nehal
    Srivastava, Sanjay K.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (10) : 1708 - 1720
  • [42] Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene
    Persson, Helena
    Kvist, Anders
    Rego, Natalia
    Staaf, Johan
    Vallon-Christersson, Johan
    Luts, Lena
    Loman, Niklas
    Jonsson, Goran
    Naya, Hugo
    Hoglund, Mattias
    Borg, Ake
    Rovira, Carlos
    CANCER RESEARCH, 2011, 71 (01) : 78 - 86
  • [43] Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
    C Uherek
    T Müller
    T Tonn
    B Uherek
    H-G Klingemann
    WS Wels
    Cancer Cell International, 4 (Suppl 1)
  • [44] A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice
    Tran, Thi
    Diniz, Mariana O.
    Dransart, Estelle
    Gey, Alain
    Merillon, Nathalie
    Lone, Yu Chun
    Godefroy, Sylvie
    Sibley, Craig
    Ferreira, Luis C. S.
    Medioni, Jacques
    Oudard, Stephane
    Johannes, Ludger
    Tartour, Eric
    CLINICAL CANCER RESEARCH, 2016, 22 (16) : 4133 - 4144
  • [45] Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu over-expressing breast tumor xenografts.
    Rimawi, M. F.
    Weiss, H. L.
    Arpino, G.
    Morris, G. S.
    Soliz, R. D.
    Ward, R. M.
    Gilmer, T. M.
    Osborne, C. K.
    Schiff, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S29 - S29
  • [46] CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model
    Nguyen-Hoai, T.
    Pham-Duc, M.
    Gries, M.
    Doerken, B.
    Pezzutto, A.
    Westermann, J.
    CANCER GENE THERAPY, 2016, 23 (06) : 162 - 167
  • [47] CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model
    T Nguyen-Hoai
    M Pham-Duc
    M Gries
    B Dörken
    A Pezzutto
    J Westermann
    Cancer Gene Therapy, 2016, 23 : 162 - 167
  • [48] Clinical validation of the concordance performance of ERBB2 status by single-cells genomics ERBB2 (HER2) amplification Assay in Circulating Tumor Cells (CTCs) from patients with matched HER2 status from metastatic tissue biopsies
    Di Caro, Giuseppe
    Lam, Ernest
    Slade, Megan
    Huang, Shuguang
    Wenstrup, Rick
    Schwartzberg, Lee
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
    Choudhury, A
    Charo, J
    Parapuram, SK
    Hunt, RC
    Hunt, DM
    Seliger, B
    Kiessling, R
    INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) : 71 - 77
  • [50] Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: New insight into the presence of the transcript variant of MUC4
    Xie, Kunling
    Zhi, Xiaofei
    Tang, Jie
    Zhu, Yi
    Zhang, Jingjing
    Li, Zheng
    Tao, Jinqiu
    Xu, Zekuan
    ONCOLOGY REPORTS, 2014, 31 (05) : 2187 - 2194